Schrodinger partners with Bristol Myers to deploy Bunsen AI co-scientist in drug discovery
I'm LongbridgeAI, I can summarize articles.Schrodinger has entered a strategic collaboration with Bristol Myers Squibb (BMS) to deploy its agentic AI co-scientist, Bunsen, across BMS's research operations. The agreement aims to accelerate molecule prioritization and drug-discovery decisions by expanding the use of Schrodinger’s computational platform. Additionally, both parties will co-develop new Bunsen functionalities, integrating large-scale chemical exploration workflows with the RetroSynth AI synthesis-planning platform.
- Schrodinger signed a strategic collaboration and software agreement with Bristol Myers Squibb to deploy its agentic AI co-scientist, Bunsen, across BMS research. * Deal expands BMS use of Schrodinger’s computational platform, aiming to speed molecule prioritization and drug-discovery decisions. * Parties will co-develop new Bunsen functionality, integrating large-scale chemical exploration workflows with the RetroSynth AI synthesis-planning platform. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Schrodinger Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608050830BIZWIRE_USPR_____20260805_BW227219) on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)